Could this be Big Tech’s ultimate healthcare flex? For years, Amazon’s ambitions in this $4 trillion market were focused on distribution: acquire a pharmacy here, a primary care network there, and offer convenience.
But more recently, rather than deploying capital to expand its fulfillment engine, Amazon exercised its cloud and AI muscle to launch tools that enable it to be a “front door” for consumers and patients. From the looks of it, the e-commerce giant has shifted, from competing for a piece of the healthcare journey to collapsing the entire journey into one company.
In any case, pharma commercialization teams may need to think about Amazon less as a new distributor and more as a disruptor of how patients, prescribers, and payers connect.
Analyzing the moves
Big Tech has upended many industries, but the highly regulated and complex healthcare industry has seemed impervious to their influence. Judging by Amazon’s most recent forays, however, this sector may not represent an innovator’s “white whale” for much longer.
Amazon has closed the “last mile” between writing a prescription and filling it. At One Medical clinics (Amazon’s primary care venture), pharmacy kiosks now let a patient walk out of an appointment with medication in hand, filled by the same company that just diagnosed them. Its oral GLP-1 management program, a recently introduced offering, takes this even further.
This year, One Medical also launched an AI-enabled assistant, with access to test results, medical history, and more. The AI agent, dubbed Health AI, can help book medical appointments or provide medical information, such as an explanation of lab results. This clearly strengthens One Medical’s abilities as a provider and can help in enhancing the patient experience all the way through drug dispensing.
More critically to pharma, Amazon’s Health AI also automatically applies manufacturer coupons and copay assistance programs for eligible patients. On the HCP side, Amazon’s integration with DoseSpot and eNavvi places patient net out-of-pocket at the point of prescribing.
Health AI subsequently moved beyond the One Medical app, embedding directly into Amazon.com and its mobile app, marking the first time the tool has been available at scale to general consumers, and further enmeshing the patient experience into the overall Amazon environment. These offerings are available to anyone, regardless of being a One Medical member.
4 potential shake-ups
The result: Screening, prescribing, fulfillment, and ongoing renewal all happen inside one Amazon-run loop. No outside touchpoint is required.
That loop doesn’t just change where a patient enters the system and picks up a prescription. It changes the nature of a healthcare “provider,” how care is delivered (including drug fulfillment), and who sees the full picture of a patient’s care.
In other words, this shift isn’t just a single disruption; it’s four separate ones. Here’s the “where” and “how” of those potential shake-ups:
- The HCP relationship: Who manages a condition over time, not just who writes the first script?
- Channel and patient experience: Who owns the point of fill, and how seamless is the drug-fulfillment experience?
- Price transparency and patient OOP: How much of a role does real-world price play, for both prescribers and patients, and how do coupon and copay assistance programs need to adapt?
- Data visibility: Does the full patient journey, from diagnosis to refill, sit outside the purview of traditional pharma data sources, or is it somehow still captured?
The four categories aren’t equally mature. And that has real implications for where pharma commercialization teams focus first.
Where pharma should focus
The first two of the above categories are already live with the GLP-1 program. That is, ongoing management of a chronic condition now sits inside Amazon’s own clinical protocol, not a patient’s existing PCP or specialist. And prescribing, fulfillment, and refill take place in a channel pharma doesn’t traditionally call upon.
GLP-1 is a favorable starting point for this model because it’s heavily consumer-driven and manageable in primary care, so the loop doesn’t need specialist judgment to run. And the GLP-1 cash-pay models give Amazon room to control pricing directly. Moreover, weight-loss management is a long-term, recurring relationship, which is exactly the kind of retention Amazon’s model is built for.
Beyond the cash market, Amazon’s ability to automatically apply coupons and copay assistance offers the opportunity for accelerated product uptake, accompanied by significant downside risks to product gross-to-net.
If your brand touches a condition that could be managed this way, GLP-1 isn’t a case study to read with curiosity. It’s a preview. Teams should be asking if and how this loop affects prescribing and fulfillment for their therapeutic area; that’s the immediate gap to close.
Conditions that depend on specialist diagnosis, complex or in-clinic administration, or those with reimbursement complexity, are a much harder fit for this model (at least for now). The therapeutic areas to watch first are protocol-friendly, primary-care-managed, chronic, and with a cash-pay market underneath.
Payers and data
Amazon’s impact on the payer space is at an earlier stage, but the signals are worth tracking closely. Amazon has already become the exclusive home delivery pharmacy for select PBM partners, including its own employee health plan. While that’s a narrow footprint today, whether it stays narrow or expands to further erode the traditional PBM mail-order business is the open question. Every new deal is a data point worth logging.
Data visibility is the slowest mover of the four categories, and possibly the hardest to predict. Cash-pay markets already have data holes. Adherence and outcomes in these markets have always been harder to capture, since the transaction doesn’t run through the claims and pharmacy systems pharma is used to watching.
The bigger exposure is what happens if this extends into broader chronic disease management. Even losing part of a patient’s journey, say the fulfillment and refill half, is enough to break the continuity pharma relies on for adherence programs and tracking the various outcome measures of marketed treatments.
Other industries offer a useful, if uncomfortable, reference point. Retail went through its own version of this: Vertically integrated fulfillment that started as a convenience play eventually became infrastructure that competitors couldn’t easily match on price or speed.
That pattern is worth keeping in mind, not as a prediction of exactly how this plays out in life sciences, but as a reminder that the “early and narrow” phase doesn’t stay that way indefinitely.
None of this is a call to panic. It’s a case for watching the right signals. The clearest one: which therapeutic area Amazon’s loop expands into next.
Photo: undefined undefined, Getty Images
As CEO, Adrienne Lovink is leading Beghou’s next phase of growth and building on its reputation as a trusted commercialization partner in life sciences. She is focused on expanding into new areas of client demand; advancing the firm’s data, AI, analytics, and technology innovation; and investing in its people and culture. Adrienne has over 25 years of experience partnering with pharmaceutical and medical device companies to advance commercialization, market access, forecasting, digital health, real-world data, and advanced analytics, including as a Partner at Trinity Life Sciences and Global Head of Real-World Data and Advanced Analytics at DRG / Clarivate.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
